Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Ratings ESG MSCI

Ratings CRISPR Therapeutics AG: Strengths and Weaknesses

Highlights: CRISPR Therapeutics AG
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Historically, the company has been releasing figures that are above expectations.
Weaknesses: CRISPR Therapeutics AG
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company has insufficient levels of profitability.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Rating Financials

CRISPR Therapeutics AG SectorUnited States

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

ROA

ROCE

-

ROE

Financial Health

-

Gearing

Leverage

-

Capital Intensity

-

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

CRISPR Therapeutics AG SectorUnited States

Global Valuation

-

Enterprise Value

-

EV/Revenue

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

CRISPR Therapeutics AG SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

CRISPR Therapeutics AG SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

CRISPR Therapeutics AG SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
470.56Cr -
BB
- -
4.92TCr
AAA
3.96TCr -
B
- -
3.47TCr -
3.44TCr
AAA
2.71TCr
A
1.62TCr - - - -
1.54TCr
BBB
1.41TCr
AA
1.3TCr
AAA
Average 2.48TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. CRSP Stock
  4. Ratings CRISPR Therapeutics AG